MedPath

Clinical Trial for Hypofractionated (4 Fraction) Heavy Ion Therapy for Ocular / Choroidal Melanoma

Phase 1
Conditions
Ocular / Choroidal Melanoma
Registration Number
JPRN-UMIN000022302
Lead Sponsor
ational Institutes for Quantum and Radiological Science and Technology National Institute of Radiological Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1. Existence of past treatment against the lesion. 2. Existence of extra-ocular lesion including metastasis. 3. Life expectancy shorter than 6 months 4. Active infection within the irradiation field 5. Existence of other active malignancies. 6. Existence of severe complications 7. Evaluated not able to complete this study because of serious medical or psychological problems

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ormal tissue acute toxicity. (to be evaluated at end of treatment, 3 months and 6 months post-treatment.
Secondary Outcome Measures
NameTimeMethod
Initial response Local control rate Normal tissue late toxicity Overall survival rate Eye retention rate
© Copyright 2025. All Rights Reserved by MedPath